Onoz Mustafa, Basaran Recep, Gucluer Berrin, Isik Nejat, Kaner Tuncay, Sav Aydin, Elmaci Ilhan
Department of Neurosurgery, Medipol University School of Medicine, Istanbul, Turkey.
APMIS. 2015 Mar;123(3):199-204. doi: 10.1111/apm.12342. Epub 2014 Dec 31.
Pituitary adenomas are the third most common intracranial tumors. Invasive adenomas account for only 0.1-0.2% of pituitary tumors. SPARC is a matrix glycoprotein that plays a role in progression and invasiveness of neoplasms. In this study, we examined the potential role of SPARC in invasive pituitary adenomas. Forty pituitary adenomas have been examined with histopathological and immunohistochemical techniques. The cohort has been classified into two groups as invasive (n = 25) and non-invasive (n = 15) utilizing the Hardy classification. Formalin fixed tissues have been stained with hematoxylin eosin. Ki-67, p53, and SPARC monoclonal antibodies have been used. We did not detect any significant difference on Ki-67, SPARC, and p53 expression patterns correlating with the pathological subtype or invasiveness. Only 24% of invasive adenomas had Ki-67 levels over 1%. A total of 67.7% non-invasive adenomas had Ki-67 levels below 1%. We did not detect any relation between SPARC levels and invasiveness of pituitary adenomas. Absence of significant SPARC expression in tumor progression, sellar dilatation, erosion and destruction suggest that SPARC scores are not related with invasiveness or progressiveness of pituitary adenomas.
垂体腺瘤是第三常见的颅内肿瘤。侵袭性腺瘤仅占垂体肿瘤的0.1 - 0.2%。富含半胱氨酸的酸性分泌蛋白（SPARC）是一种基质糖蛋白，在肿瘤的进展和侵袭中起作用。在本研究中，我们检测了SPARC在侵袭性垂体腺瘤中的潜在作用。采用组织病理学和免疫组织化学技术对40例垂体腺瘤进行了检测。利用哈代分类法将该队列分为侵袭性（n = 25）和非侵袭性（n = 15）两组。福尔马林固定的组织用苏木精伊红染色。使用了Ki-67、p53和SPARC单克隆抗体。我们未检测到Ki-67、SPARC和p53表达模式与病理亚型或侵袭性之间存在任何显著差异。仅24%的侵袭性腺瘤Ki-67水平超过1%。共有67.7%的非侵袭性腺瘤Ki-67水平低于1%。我们未检测到SPARC水平与垂体腺瘤侵袭性之间存在任何关联。肿瘤进展、蝶鞍扩张、侵蚀和破坏中缺乏显著的SPARC表达表明SPARC评分与垂体腺瘤的侵袭性或进展性无关。
